{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:18Z","timestamp":1792723098313,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e00951","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:49:37Z","timestamp":1782791377000},"page":"e00951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neurological complications of current and emerging CAR-T cell therapies"],"prefix":"10.1016","volume":"23","author":[{"given":"Anna G.","family":"Hauswirth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/bmjonc-2024-000566","article-title":"Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges","volume":"4","author":"Chen","year":"2025","journal-title":"BMJ Oncology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib3","doi-asserted-by":"crossref","first-page":"ltae005","DOI":"10.1093\/immadv\/ltae005","article-title":"Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review","volume":"5","author":"Dewaele","year":"2025","journal-title":"Immunotherapy Advances"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00951_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41582-025-01112-8","article-title":"Neurological complications of CAR T cell therapy for cancers","volume":"21","author":"Karschnia","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00951_bib7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"issue":"8046","key":"10.1016\/j.neurot.2026.e00951_bib8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00951_bib9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00951_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-Targeted T-Cell\u2013Engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00951_bib11","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-Cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00951_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease \u2014 a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00951_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025028964","article-title":"Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy","author":"Kaulen","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcyt.2024.07.015","article-title":"Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid","volume":"27","author":"De Philippis","year":"2025","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib16","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200515","article-title":"Immune effector cell\u2013associated neurotoxicity delayed relapse after chimeric antigen receptor T-Cell therapy: a case report","volume":"13","author":"Favero","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00951_bib18","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"Wires Mechanisms of Disease"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00951_bib20","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00951_bib21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00951_bib22","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00951_bib23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00951_bib24","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","volume":"24","author":"Shalabi","year":"2022","journal-title":"Neuro Oncol"},{"issue":"10254","key":"10.1016\/j.neurot.2026.e00951_bib25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit Care Med"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00951_bib28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00951_bib29","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jamaneurol.2024.2506","article-title":"Parkinsonism following chimeric antigen receptor T cell therapy","volume":"81","author":"Gudera","year":"2024","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00951_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00951_bib31","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"0","key":"10.1016\/j.neurot.2026.e00951_bib32","article-title":"Non-ICANS neurologic events in patients with relapsed\/refractory multiple myeloma treated with ciltacabtagene Autoleucel: clinical presentation and management in CARTITUDE studies","volume":"0","author":"Rodr\u00edguez-Otero","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.neurot.2026.e00951_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103453","article-title":"Rethinking mechanisms of neurotoxicity with BCMA directed therapy","volume":"166","author":"Mohyuddin","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of On-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella","year":"2022","journal-title":"J Histochem Cytochem"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib36","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT practice harmonisation and guidelines committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"issue":"15_supplement","key":"10.1016\/j.neurot.2026.e00951_bib37","doi-asserted-by":"crossref","first-page":"P3.6","DOI":"10.1212\/WNL.92.15_supplement.P3.6-009","article-title":"Ischemic stroke after CAR-T cell therapy (P3.6-009)","volume":"92","author":"Shah","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00951_bib38","first-page":"194","article-title":"Immune effector cell-associated acute stroke: a novel entity?","author":"Mauget","year":"2023","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00951_bib39","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Bufalo","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00951_bib40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12185-021-03160-4","article-title":"Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient","volume":"114","author":"xia","year":"2021","journal-title":"Int J Hematol"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00951_bib41","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood.2024025679","article-title":"Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy","volume":"144","author":"Desch\u00eanes-Simard","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00951_bib42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/19418744231167290","article-title":"Chimeric antigen Receptor-T cell mediated bilateral facial nerve palsy: a case report","volume":"13","author":"Patrick","year":"2023","journal-title":"Neurohospitalist"},{"issue":"Supplement 1","key":"10.1016\/j.neurot.2026.e00951_bib43","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2023-178743","article-title":"Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and Cartitude-4 studies of ciltacabtagene autoleucel (Cilta-cel)","volume":"142","author":"Van De Donk","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib44","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.21873\/invivo.12640","article-title":"Severe motor weakness due to disturbance in peripheral nerves following Tisagenlecleucel treatment","volume":"35","author":"Kuboki","year":"2021","journal-title":"In Vivo (Brooklyn)"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00951_bib45","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/hon.2976","article-title":"Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy","volume":"40","author":"Catal\u00e1","year":"2022","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib46","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.25794","article-title":"Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma","volume":"95","author":"El Chaer","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neurot.2026.e00951_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2020.11.021","article-title":"Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: an unexpected case of fludarabine-associated progressive leukoencephalopathy","volume":"144","author":"Winter","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00951_bib48","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2010.04.003","article-title":"Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation","volume":"17","author":"Beitinjaneh","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00951_bib49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","article-title":"Fludarabine and neurotoxicity in engineered T-cell therapy","volume":"25","author":"Lowe","year":"2018","journal-title":"Gene Ther"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00951_bib50","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00951_bib51","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s13402-024-00945-7","article-title":"Rituximab potentially improves clinical outcomes of CAR-T therapy for r\/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion","volume":"47","author":"Li","year":"2024","journal-title":"Cell Oncol"},{"key":"10.1016\/j.neurot.2026.e00951_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"13","author":"Albarr\u00e1n","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00951_bib54","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","article-title":"Immunotherapy-related cognitive impairment after CAR T cell therapy in mice","volume":"188","author":"Geraghty","year":"2025","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00951_bib55","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/cncr.27854","article-title":"Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials","volume":"119","author":"Hui","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib56","doi-asserted-by":"crossref","first-page":"236.e1","DOI":"10.1016\/j.jtct.2025.01.886","article-title":"Long-term cognitive outcomes in adult patients receiving chimeric antigen receptor T-Cell therapies","volume":"31","author":"Barata","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib57","doi-asserted-by":"crossref","first-page":"305.e1","DOI":"10.1016\/j.jtct.2022.03.023","article-title":"Change in neurocognitive performance among patients with non-hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy","volume":"28","author":"Hoogland","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00951_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1212\/WNL.0000000000201083","article-title":"Long-term neurologic safety in patients with B-Cell lymphoma treated with Anti-CD19 chimeric antigen receptor T-Cell therapy","volume":"99","author":"Ursu","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib59","doi-asserted-by":"crossref","first-page":"254.e1","DOI":"10.1016\/j.jtct.2023.01.004","article-title":"Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T","volume":"29","author":"Akinola","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib60","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40487-021-00174-0","article-title":"Patient perspectives on health-related quality of life in diffuse large B-Cell lymphoma treated with car T-Cell therapy: a qualitative study","volume":"10","author":"Cheng","year":"2022","journal-title":"Oncol Ther"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00951_bib61","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.jtct.2022.05.015","article-title":"Change in patients' perceived cognition following chimeric antigen receptor T-Cell therapy for lymphoma","volume":"28","author":"Barata","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.neurot.2026.e00951_bib63","series-title":"Fda, Cber. February 5, 2026 Approval Letter - YESCARTA","year":"2026"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00951_bib64","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat Med"},{"issue":"7903","key":"10.1016\/j.neurot.2026.e00951_bib65","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-025-01760-9","article-title":"Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting","volume":"18","author":"Li","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"10494","key":"10.1016\/j.neurot.2026.e00951_bib67","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00951_bib68","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jamaoncol.2024.3891","article-title":"Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: a nonrandomized clinical trial","volume":"10","author":"Chen","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00951_bib69","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T-cells in metastatic castration resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00951_bib70","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib71","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00951_bib72","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase i trial of regional mesothelin-targeted car t-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013pd-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib73","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"8047","key":"10.1016\/j.neurot.2026.e00951_bib74","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2024","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00951_bib75","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.neurot.2026.e00951_bib76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02229","article-title":"STRIvE-02: a first-in-human phase i study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors","author":"Pinto","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00951_bib77","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted allogeneic CAR T-Cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00951_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00951_bib79","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.neurot.2026.e00951_bib80","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/blood-2023-187252","article-title":"Updated results of the phase I BALLI-01 trial of UCART22 process 2 (P2), an Anti-CD22 allogeneic CAR-T cell product manufactured by Cellectis biologics, in patients with relapsed or refractory (R\/R) CD22+ B-Cell acute lymphoblastic leukemia (B-ALL)","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00951_bib81","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib82","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"10473","key":"10.1016\/j.neurot.2026.e00951_bib83","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib84","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00951_bib85","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00951_bib86","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00951_bib87","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"10379","key":"10.1016\/j.neurot.2026.e00951_bib88","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00951_bib89","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00951_bib90","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00951_bib91","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00951_bib92","series-title":"NCCN Guidelines version 2.2026 management of CAR T-Cell and lymphocyte engager-related toxicities NCCN Guidelines Panel disclosures","author":"Schneider","year":"2025"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00951_bib93","first-page":"2443","article-title":"How I treat unique and difficult-to-manage cases of CAR T-cell therapy\u2013associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00951_bib94","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00951_bib95","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00951_bib96","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/cncr.35316","article-title":"Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia","volume":"130","author":"Wang","year":"2024","journal-title":"Cancer"},{"issue":"35","key":"10.1016\/j.neurot.2026.e00951_bib97","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.neurot.2026.e00951_bib98","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2023-186585","article-title":"Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity","volume":"142","author":"Solh","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00951_bib99","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.neurot.2026.e00951_bib100","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-25-4817","article-title":"The conflicting role of myeloid cells in CAR-T cell therapy","author":"DeFranco","year":"2026","journal-title":"Cancer Res"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:54:26Z","timestamp":1792720466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926001212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926001212"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00951","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological complications of current and emerging CAR-T cell therapies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00951"}}